Komori
Share Issuance and Disposal4586Medrx Co.,Ltd.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 35th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms)

In September 2026, 14,770 Series 35 Stock Acquisition Rights were exercised, and 1,477,000 new shares were delivered. As of the end of the month, 41,395 Stock Acquisition Rights (4,139,500 shares) remained unexercised.

Worth reading
60In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1477000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of the Series 35 Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)

発行・処分する株式数

Number of shares delivered during the month: 1,477,000 shares (1,477,000 new shares and 0 treasury shares transferred)

Intended allottee
グロース・キャピタル株式会社 (allottee of these Stock Acquisition Rights)
発行済株式総数

Exercise ratio subject to exercise restrictions: 2.49% (1,477,000 shares delivered across all series / 59,365,100 listed shares as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥62, ¥54, ¥55 and ¥56. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition Rights
Total issued: 147,820; exercised during the month: 14,770; unexercised at the end of the preceding month: 56,165; unexercised at the end of the month: 41,395
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to exercise restrictions is 2.49%.
Most recent equity financing
Issued on 5 June 2026: Series 35 Stock Acquisition Rights (with an exercise price adjustment clause), allotted to グロース・キャピタル株式会社. Total issued: 147,820. Issue price and funds raised: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of the Series 35 Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 1,477,000 shares (1,477,000 new shares and 0 treasury shares transferred)
Intended allotteeグロース・キャピタル株式会社 (allottee of these Stock Acquisition Rights)
Dilution RateExercise ratio subject to exercise restrictions: 2.49% (1,477,000 shares delivered across all series / 59,365,100 listed shares as of the payment date for the issuance)
Total number of issued shares68,530,600 shares (as of the end of the month preceding the target month) → Not disclosed
Exercise priceExercise prices during the month: ¥62, ¥54, ¥55 and ¥56. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition RightsTotal issued: 147,820; exercised during the month: 14,770; unexercised at the end of the preceding month: 56,165; unexercised at the end of the month: 41,395
Procedures under the Corporate Code of ConductDescribes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to exercise restrictions is 2.49%.
Most recent equity financingIssued on 5 June 2026: Series 35 Stock Acquisition Rights (with an exercise price adjustment clause), allotted to グロース・キャピタル株式会社. Total issued: 147,820. Issue price and funds raised: Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the Series 35 Stock Acquisition Rights in September 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 35th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms) | Medrx Co.,Ltd. (4586) timely disclosure | Komori